Overview

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeyondBio Inc.

Treatments:

Capecitabine